• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Increasing Prevalence of infertility is expected to drive the global Assisted Reproductive technology (ART) market during the forecast period 10% CAGR

    Assisted Reproductive Technology Market to estimate significant CAGR during forecast period 2018-2023

    Report Details:
    15 Companies Covered
    200 Pages

    Pune, India, September 2018/MRFR Press Release/- Market Research Future published a half-cooked research report on the global assisted reproductive technology (ART) market.


    Assisted Reproductive Technology Market Report Highlights


    The assisted reproductive technology (ART) market is expected to witness tremendous growth owing to the rising prevalence of infertility in males as well as females. Other key factors such as the growing obesity among population, rising ovulation disorders, change to sedentary lifestyle, socioeconomic factors like postponement of marriage due to unemployment and others, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian and endometrial cancer, increase in smoking and alcohol consumption are contributing towards the growth.  However, factors such as, lower success rate, the high cost of assisted reproductive technology procedures, expensive treatments, raising ethical issues, chances of birth defects, the risk of prematurity and low birth weight in newborns and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.


    Segmentation


    The global assisted reproductive technology market is segmented on the basis of diagnosis, type, and end-user. The assisted reproductive technology market, by diagnosis, is categorized into ovulation testing, hysterosalpingography, ovarian reserve testing, genetic testing, other hormone testing and imaging tests. On the basis of type, the market is segmented into Ovulation Induction (OI),  Artificial Insemination (AI), Donor Conception, In-Vitro Fertilization (IVF), Gamete Intrafallopian Transfer (GIFT), Intracytoplasmic Sperm Injection (ICSI), Preimplantation Genetic Diagnosis (PGD) and Surrogacy. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and IVF Centers and others


    Access Report @ https://www.marketresearchfuture.com/reports/assisted-reproductive-technology-market-6359


    Regional Analysis


    Europe (UK, Belgium, France, and Netherlands) is the largest in the market owing to the increasing prevalence of obesity and growing healthcare expenditure. As per the World Health Organization, 23% of the women in Europe were obese in 2014.


    The Americas is the second largest the assisted reproductive technology (ART) market during the forecast period. The increasing occurrence of ovarian cancer drives the market in this region. The American Cancer Society estimated that in 2018, 22,240 women are likely to be diagnosed with ovarian cancer. This is expected to influence the market growth during the forecast period.  


    Asia-Pacific was projected to be the fastest growing region for the global assisted reproductive technology (ART) market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the Virtus Health 2018, infertility affects one in six Australian couples of the reproductive age. This is expected to provide favorable backgrounds for the market to grow.


    The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.


    Key Players


    Some of the key players in the global assisted reproductive technology (ART) market are Cosmos Biomedical Limited, California Cryobank, Bloom IVF Centre, Cryolab Ltd., Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Cooper Surgical, Inc, Ferring Pharmaceuticals, European Sperm Bank, Irvine Scientific and Hamilton Throne Ltd.